City Therapeutics (Ticker: CTY US) is a United States clinical biotech company developing RNA interference (RNAi) therapeutics to silence disease-relevant proteins. Its programs focus on thromboembolic diseases, Type 1 Stargardt disease, and anemia associated with chronic disease.

City Therapeutics expects to list on NASDAQ on October 16, 2026. The proposed offering comprises 9.72 million shares, priced at an indicative range of USD 17.00–19.00 each. At the indicative range midpoint, the base offering would raise approximately USD 174.96 million in gross proceeds. The reported IPO market capitalization is approximately USD 905.98 million; a separate upper valuation of $956.3 million is cited for the IPO. IPO proceeds are intended to fund clinical trials, advance the RNAi platform, and support working capital and general corporate purposes.

For the 12 months ended June 30, 2026, the company reported revenue of $14.34 million and a net loss of $87.67 million. Its lead candidate, CITY-FXI, is a GalNAc-conjugated siRNA therapeutic targeting Factor XI, in development for the prevention of thromboembolic diseases.

Goldman Sachs, Jefferies, Stifel and Oppenheimer & Co. will act as offering managers for the transaction.